|1.||Pinchuk, Anatoly N: 1 article (04/2006)|
|2.||Rampy, Mark A: 1 article (04/2006)|
|3.||Gross, Milton D: 1 article (04/2006)|
|4.||Counsell, Raymond E: 1 article (04/2006)|
|5.||Skinner, R W Scott: 1 article (04/2006)|
|6.||Weichert, Jamey P: 1 article (04/2006)|
|7.||Longino, Marc A: 1 article (04/2006)|
04/06/2006 - "These results strongly suggest that extension of the human trials to include other cancers is warranted, especially when NM-404 is radiolabeled with iodine-124, a new commercially available positron-emitting isotope. "
04/06/2006 - "On the basis of imaging and tissue distribution studies in several rodent tumor models, the C18 analogue, NM-404, was chosen for follow-up evaluation in human lung cancer patients. "
04/06/2006 - "A direct comparison between NM-404 and its predecessor, NM-324, in human PC-3 tumor bearing immune-compromised mice revealed a dramatic enhancement in both tumor uptake and total body elimination of NM-404 relative to NM-324. "
|2.||Lung Neoplasms (Lung Cancer)